Untargeted Metabolomics of Feces Reveals Diagnostic and Prognostic Biomarkers for Active Tuberculosis and Latent Tuberculosis Infection: Potential Application for Precise and Non-Invasive Identification

Overview

Journal Infect Drug Resist

Publisher Dove Medical Press

Date 2023 Sep 18

PMID 37719654

Authors

Dan Luo

Bo-Yi Yang

Kai Qin

Chong-Yu Shi

Nian-Sa Wei

Hai Li

Yi-Xiang Qin

Gang Liu

Xiao-Ling Qin

Shi-Yi Chen

Xiao-Jing Guo

Li Gan

Ruo-Lan Xu

Bai-Qing Dong

Jing Li

Affiliations

Soon will be listed here.

Abstract

Purpose: Distinguishing latent tuberculosis infection (LTBI) from active tuberculosis (ATB) is important to control the prevalence of tuberculosis; however, there is currently no effective method. The aim of this study was to discover specific metabolites through fecal untargeted metabolomics to discriminate ATB, individuals with LTBI, and healthy controls (HC) and to probe the metabolic perturbation associated with the progression of tuberculosis.

Patients And Methods: Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was performed to comprehensively detect compounds in fecal samples from HC, LTBI, and ATB patients. Differential metabolites between the two groups were screened, and their underlying biological functions were explored. Candidate metabolites were selected and enrolled in LASSO regression analysis to construct diagnostic signatures for discriminating between HC, LTBI, and ATB. A receiver operating characteristic (ROC) curve was applied to evaluate diagnostic value. A nomogram was constructed to predict the risk of progression of LTBI.

Results: A total of 35 metabolites were found to exist differentially in HC, LTBI, and ATB, and eight biomarkers were selected. Three diagnostic signatures based on the eight biomarkers were constructed to distinguish between HC, LTBI, and ATB, demonstrating excellent discrimination performance in ROC analysis. A nomogram was successfully constructed to evaluate the risk of progression of LTBI to ATB. Moreover, 3,4-dimethylbenzoic acid has been shown to distinguish ATB patients with different responses to etiological tests.

Conclusion: This study constructed diagnostic signatures based on fecal metabolic biomarkers that effectively discriminated HC, LTBI, and ATB, and established a predictive model to evaluate the risk of progression of LTBI to ATB. The results provide scientific evidence for establishing an accurate, sensitive, and noninvasive differential diagnosis scheme for tuberculosis.

References

Che N, Cheng J, Li H, Zhang Z, Zhang X, Ding Z . Decreased serum 5-oxoproline in TB patients is associated with pathological damage of the lung. Clin Chim Acta. 2013; 423:5-9. DOI: 10.1016/j.cca.2013.04.010. View

Conde R, Laires R, Goncalves L, Rizvi A, Barroso C, Villar M . Discovery of serum biomarkers for diagnosis of tuberculosis by NMR metabolomics including cross-validation with a second cohort. Biomed J. 2021; 45(4):654-664. PMC: 9486122. DOI: 10.1016/j.bj.2021.07.006. View

Tovaglieri A, Sontheimer-Phelps A, Geirnaert A, Prantil-Baun R, Camacho D, Chou D . Species-specific enhancement of enterohemorrhagic E. coli pathogenesis mediated by microbiome metabolites. Microbiome. 2019; 7(1):43. PMC: 6425591. DOI: 10.1186/s40168-019-0650-5. View

Kurihara S . Polyamine metabolism and transport in gut microbes. Biosci Biotechnol Biochem. 2022; 86(8):957-966. DOI: 10.1093/bbb/zbac080. View

Mahapatra S, Hess A, Johnson J, Eisenach K, DeGroote M, Gitta P . A metabolic biosignature of early response to anti-tuberculosis treatment. BMC Infect Dis. 2014; 14:53. PMC: 3918231. DOI: 10.1186/1471-2334-14-53. View

Ye S, Wang L, Li S, Ding Q, Wang Y, Wan X . The correlation between dysfunctional intestinal flora and pathology feature of patients with pulmonary tuberculosis. Front Cell Infect Microbiol. 2023; 12:1090889. PMC: 9811264. DOI: 10.3389/fcimb.2022.1090889. View

Namasivayam S, Maiga M, Yuan W, Thovarai V, Costa D, Mittereder L . Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy. Microbiome. 2017; 5(1):71. PMC: 5501520. DOI: 10.1186/s40168-017-0286-2. View

Yerlikaya S, Broger T, Maclean E, Pai M, Denkinger C . A tuberculosis biomarker database: the key to novel TB diagnostics. Int J Infect Dis. 2017; 56:253-257. DOI: 10.1016/j.ijid.2017.01.025. View

Pai M, Denkinger C, Kik S, Rangaka M, Zwerling A, Oxlade O . Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev. 2014; 27(1):3-20. PMC: 3910908. DOI: 10.1128/CMR.00034-13. View

10.

Blumberg H, Ernst J . The Challenge of Latent TB Infection. JAMA. 2016; 316(9):931-3. PMC: 5319563. DOI: 10.1001/jama.2016.11021. View

11.

Dang A, Marsland B . Microbes, metabolites, and the gut-lung axis. Mucosal Immunol. 2019; 12(4):843-850. DOI: 10.1038/s41385-019-0160-6. View

12.

Shah M, Reed C . Complications of tuberculosis. Curr Opin Infect Dis. 2014; 27(5):403-10. DOI: 10.1097/QCO.0000000000000090. View

13.

Michalovich D, Rodriguez-Perez N, Smolinska S, Pirozynski M, Mayhew D, Uddin S . Obesity and disease severity magnify disturbed microbiome-immune interactions in asthma patients. Nat Commun. 2019; 10(1):5711. PMC: 6911092. DOI: 10.1038/s41467-019-13751-9. View

14.

Andreas N, Roy R, Gomez-Romero M, Horneffer-van der Sluis V, Lewis M, Camuzeaux S . Performance of metabonomic serum analysis for diagnostics in paediatric tuberculosis. Sci Rep. 2020; 10(1):7302. PMC: 7190829. DOI: 10.1038/s41598-020-64413-6. View

15.

Hunter R . Tuberculosis as a three-act play: A new paradigm for the pathogenesis of pulmonary tuberculosis. Tuberculosis (Edinb). 2016; 97:8-17. PMC: 4795183. DOI: 10.1016/j.tube.2015.11.010. View

16.

Scher J, Pillinger M . The anti-inflammatory effects of prostaglandins. J Investig Med. 2009; 57(6):703-8. DOI: 10.2310/JIM.0b013e31819aaa76. View

17.

Luo M, Liu Y, Wu P, Luo D, Sun Q, Zheng H . Alternation of Gut Microbiota in Patients with Pulmonary Tuberculosis. Front Physiol. 2017; 8:822. PMC: 5698276. DOI: 10.3389/fphys.2017.00822. View

18.

Izquierdo-Garcia J, Comella-Del-Barrio P, Campos-Olivas R, Villar-Hernandez R, Prat-Aymerich C, de Souza-Galvao M . Discovery and validation of an NMR-based metabolomic profile in urine as TB biomarker. Sci Rep. 2020; 10(1):22317. PMC: 7749110. DOI: 10.1038/s41598-020-78999-4. View

19.

Want E, Masson P, Michopoulos F, Wilson I, Theodoridis G, Plumb R . Global metabolic profiling of animal and human tissues via UPLC-MS. Nat Protoc. 2012; 8(1):17-32. DOI: 10.1038/nprot.2012.135. View

20.

Zhang X, Huang T, Wu Y, Peng W, Xie H, Pan M . Inhibition of the PI3K-Akt-mTOR signaling pathway in T lymphocytes in patients with active tuberculosis. Int J Infect Dis. 2017; 59:110-117. DOI: 10.1016/j.ijid.2017.04.004. View